Endurant Capital Management’s Fate Therapeutics FATE Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-71,640
Closed -$1.77M 57
2022
Q2
$1.77M Buy
71,640
+11,908
+20% +$329K 0.68% 36
2022
Q1
$2.32M Buy
59,732
+22,407
+60% +$868K 0.7% 36
2021
Q4
$2.18M Buy
+37,325
New +$2.12M 0.59% 39
2021
Q3
Sell
-51,031
Closed -$4.43M 56
2021
Q2
$4.43M Buy
51,031
+37,599
+280% +$3.03M 1.22% 32
2021
Q1
$1.11M Sell
13,432
-53,153
-80% -$5.09M 0.3% 55
2020
Q4
$6.05M Buy
66,585
+10,375
+18% +$644K 2.18% 15
2020
Q3
$2.25M Sell
56,210
-4,682
-8% -$163K 0.78% 40
2020
Q2
$2.09M Buy
60,892
+20,160
+49% +$601K 0.85% 40
2020
Q1
$905K Sell
40,732
-94,290
-70% -$2.38M 0.41% 37
2019
Q4
$2.64M Sell
135,022
-31,760
-19% -$504K 0.85% 31
2019
Q3
$2.59M Buy
+166,782
New +$3.2M 1% 24
2018
Q4
Sell
-204,333
Closed -$3.33M 61
2018
Q3
$3.33M Buy
204,333
+121,761
+147% +$1.44M 1.48% 26
2018
Q2
$936K Sell
82,572
-72,772
-47% -$802K 0.41% 46
2018
Q1
$1.52M Sell
155,344
-401,335
-72% -$3.84M 0.57% 43
2017
Q4
$3.4M Buy
556,679
+283,979
+104% +$1.27M 1.04% 37
2017
Q3
$1.08M Buy
+272,700
New +$927K 0.33% 67

Other funds holding FATE